Using a model of incarcerated individuals and
hepatitis C virus infection transmission among people who inject drugs
in England, researchers found that increased treatment and shorter
duration direct-acting antiviral therapy may be more cost-effective
compared with case-finding and current treatment methods, according to
findings published in Hepatology.
“Our model shows that baseline [or] existing
levels of HCV treatment for [people who inject drugs] in prison and the
community are unlikely to result in observable changes in HCV chronic
prevalence or incidence among [people who inject drugs] in prison in the
next 50 years,” Natasha K. Martin, DPhil, associate professor, division of global public health, University of California San Diego, and colleagues wrote.
Natasha K. Martin
To assess the cost-effectiveness of increased
HCV case-finding and treatment in UK prisons with shorter durations of
therapy, the researchers used a model that measured the
cost-effectiveness of doubling HCV case-finding and increasing treatment
in UK prisons then compared it with status quo voluntary risk-based
testing. These were compared using both currently recommended therapies
(8-24 weeks) or interferon (IFN)-free direct-acting antivirals (DAAs;
8-12 weeks).
The researchers used costs (British pounds)
and quality-adjusted life years (QALY) to calculate mean incremental
cost-effectiveness ratios (ICERs).
“We assumed 56% referral and 2.5% [of] 25% of
referred people who inject drugs (PWID) [or former users] were treated
within 2 months of diagnosis in prison,” the researchers wrote. “PWID
and [former users] are in prison an average [of] 4 and 8 months,
respectively.”
Overall, the model showed that doubling prison
HCV testing rates with existing treatments had a mean ICER of 19,850
pounds per QALY gained compared with current testing or treatment. This
indicated that this method is 45% likely to be cost-effective under a
20,000 pounds’ willingness-to-pay threshold, according to the abstract.
Switching to an 8- to 12-week IFN-free DAA regimen in prisons may
increase cost-effectiveness (ICER: 15,090 pounds per QALY gained).
Excluding prevention benefit decreases this cost-effectiveness.
In addition, if more than 10% of prisoners who
are referred PWID are treated in prison, either treatment could be
highly cost-effective (ICER: less than 13,000 pounds). HCV case-finding
and IFN-free DAAs could be highly cost-effective if DAA cost is 10%
lower or with 8 weeks' duration.
The researchers concluded: “Increased HCV
testing in UK prisons is borderline cost-effective compared to status
quo voluntary risk-based testing under a 20,000 [pounds] willingness to
pay with current treatments, but likely to be cost-effective if
short-course IFN-free DAAs are used and could be highly cost-effective
if PWID treatment rates were increased.” – by Melinda Stevens
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.